Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07083362
PHASE1

Safety, Tolerability and Pharmacokinetic Study of HRS-8829

Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd

View on ClinicalTrials.gov

Summary

This study adopted a single-center, randomized, double-blind, placebo-controlled, dose-escalation design and was divided into two parts: single-dose dose-escalation (SAD) and multiple-dose dose-escalation (MAD)

Official title: Safety, Tolerability and Pharmacokinetic Studies of Single and Multiple Administrations of HRS-8829 in Healthy Subjects

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

70

Start Date

2025-07

Completion Date

2025-11

Last Updated

2025-07-24

Healthy Volunteers

Yes

Interventions

DRUG

HRS-8829;Placebo

Subject will receive HRS-8829 at dose level 1. Subject will receive placebo at dose level 1.

DRUG

HRS-8829;Placebo

Subject will receive HRS-8829 at dose level 2. Subject will receive placebo at dose level 2.

DRUG

HRS-8829;Placebo

Subject will receive HRS-8829 at dose level 3. Subject will receive placebo at dose level 3.

DRUG

HRS-8829;Placebo

Subject will receive HRS-8829 at dose level 4. Subject will receive placebo at dose level 4.

Locations (1)

Beijing Anzhen Hospital, Capital Medical University

Beijing, Beijing Municipality, China